Kalydeco

Kalydeco (Ivacaftor) is a groundbreaking medication for Cystic Fibrosis (CF)—it’s the first to treat the underlying cause of CF rather than the symptoms of the disease. 2022 marked the 10th anniversary of the medication’s approval by the U.S. Food and Drug Administration (FDA), and communicating this milestone internally was one of Vertex Pharmaceuticals' key objectives for the year, but they didn’t quite know how to do it.